Glylorin: Began a multicenter Phase III trial with Glylorin to treat the skin disease.

The compound, a 15 percent concentration of glycerol monolaurate applied topically twice a day for three months, is an anti-inflammatory, broad spectrum anti-bacterial and anti-proliferative drug that...